Unknown

Dataset Information

0

Adaptive Lung Radiation Therapy in the Era of Immunotherapy: A Single-Center Retrospective Study.


ABSTRACT:

Purpose

Treatment for locally advanced non-small cell lung cancer consists of concurrent chemoradiation followed by immunotherapy. Though this combination has been shown to have a benefit in both progression-free survival and overall survival, treatment is often limited by the development of pneumonitis. One way to mitigate toxicity is through adaptive radiation therapy, which does not currently have a standardized implementation in clinical practice.

Methods and materials

A single-center retrospective review of patients with locally advanced stage III or oligometastatic stage IV non-small cell lung cancer who were treated with chemoradiation with concurrent or subsequent immunotherapy from 2015 to 2020 was performed. Patients were stratified based on having 1 or more offline adapted plan. The aim of this study was to evaluate the association between dose-volume histogram values and common toxicities experienced during this treatment, including pneumonitis and esophagitis.

Results

Twenty-five patients were included in the final analysis: 10 with adapted plans (AP), and 15 with nonadapted plans (NAP). Mean age at onset was 74 years. The most common histology was adenocarcinoma (N = 13). Five patients experienced pneumonitis: 2 in AP and 3 in NAP. Mann-Whitney U test of gross tumor volume sizes between AP (346.2 ± 269.7 cm3) and NAP (153.1 ± 99.6 cm3) was significant (P = .019). Multiple linear regression analysis with adjustment for covariates of pneumonitis versus plan adaptation (P = .106) and esophagitis versus plan adaptation (P = .59) did not demonstrate a significant difference in toxicity between the adapted and nonadaptive patients.

Conclusions

Despite similar toxicities in both groups, the gross tumor volume size in the AP was more than double compared with NAP, suggesting that adaptive techniques provide a method for patients with larger target volumes to be treated without an observed difference in pneumonitis rates. These results suggest adaptive radiation therapy may have a role in mitigating toxicity experience from chemoradiation and immunotherapy and warrants further investigation.

SUBMITTER: Portal D 

PROVIDER: S-EPMC10801661 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adaptive Lung Radiation Therapy in the Era of Immunotherapy: A Single-Center Retrospective Study.

Portal Daniella D   Lu Shou-En SE   Piperdi Huzaifa H   Jabbour Salma K SK   Reyhan Meral M  

Advances in radiation oncology 20230710 1


<h4>Purpose</h4>Treatment for locally advanced non-small cell lung cancer consists of concurrent chemoradiation followed by immunotherapy. Though this combination has been shown to have a benefit in both progression-free survival and overall survival, treatment is often limited by the development of pneumonitis. One way to mitigate toxicity is through adaptive radiation therapy, which does not currently have a standardized implementation in clinical practice.<h4>Methods and materials</h4>A singl  ...[more]

Similar Datasets

| S-EPMC11657634 | biostudies-literature
| S-EPMC10577828 | biostudies-literature
| S-EPMC7163098 | biostudies-literature
| S-EPMC8264679 | biostudies-literature
| S-EPMC6724320 | biostudies-literature
| S-EPMC10865094 | biostudies-literature
| S-EPMC4430492 | biostudies-literature
| S-EPMC10864119 | biostudies-literature
| S-EPMC11921175 | biostudies-literature
| S-EPMC10664336 | biostudies-literature